{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:15:22Z","timestamp":1790032522992,"version":"4.0.1"},"reference-count":28,"publisher":"Society of Nuclear Medicine","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.2967\/jnumed.123.266381","type":"journal-article","created":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T16:10:20Z","timestamp":1701447020000},"page":"1941-1948","source":"Crossref","is-referenced-by-count":35,"title":["Preclinical Evaluation of a Radiotheranostic Single-Domain Antibody Against Fibroblast Activation Protein \u03b1"],"prefix":"10.2967","volume":"64","author":[{"given":"Yana","family":"Dekempeneer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Massa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Santens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Berdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa Miranda","family":"Lucero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Rita","family":"Pombo Antunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Lahoutte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo A.","family":"Van Ginderachter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Devoogdt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"D\u2019Huyvetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2023,12,1]]},"reference":[{"key":"2023120108101142000_64.12.1941.1","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41573-020-0073-9","article-title":"Radiopharmaceutical therapy in cancer: clinical advances and challenges","volume":"19","author":"Sgouros","year":"2020","journal-title":"Nat Rev Drug Discov."},{"key":"2023120108101142000_64.12.1941.2","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.2014.941803"},{"key":"2023120108101142000_64.12.1941.3","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1080\/14712598.2016.1185412","article-title":"Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle","volume":"16","author":"Dekempeneer","year":"2016","journal-title":"Expert Opin Biol Ther."},{"key":"2023120108101142000_64.12.1941.4","doi-asserted-by":"crossref","first-page":"941832","DOI":"10.3389\/fendo.2022.941832","article-title":"The evolution of PRRT for the treatment of neuroendocrine tumors: what comes next?","volume":"13","author":"Harris","year":"2022","journal-title":"Front Endocrinol (Lausanne)."},{"key":"2023120108101142000_64.12.1941.5","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1158\/1078-0432.CCR-22-2875","article-title":"FDA approval summary: lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer","volume":"29","author":"Fallah","year":"2023","journal-title":"Clin Cancer Res."},{"key":"2023120108101142000_64.12.1941.6","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/bs.ircmb.2022.03.010","article-title":"Emerging applications of nanobodies in cancer therapy","volume":"369","author":"Awad","year":"2022","journal-title":"Int Rev Cell Mol Biol."},{"key":"2023120108101142000_64.12.1941.7","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.263907"},{"key":"2023120108101142000_64.12.1941.8","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-018-0275-3"},{"key":"2023120108101142000_64.12.1941.9","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.7150\/thno.69475","article-title":"Fibroblast activation protein-based theranostics in cancer research: a state-of-the-art review","volume":"12","author":"Zhao","year":"2022","journal-title":"Theranostics."},{"key":"2023120108101142000_64.12.1941.10","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.112.265140"},{"key":"2023120108101142000_64.12.1941.11","doi-asserted-by":"publisher","DOI":"10.1021\/bp049830x"},{"key":"2023120108101142000_64.12.1941.12","doi-asserted-by":"publisher","DOI":"10.1096\/fj.10-180331"},{"key":"2023120108101142000_64.12.1941.13","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1158\/1535-7163.MCT-21-1021","article-title":"Preclinical evaluation of 225Ac-labeled single domain antibody for the treatment of HER2pos cancer","volume":"21","author":"Rodak","year":"2022","journal-title":"Mol Cancer Ther."},{"key":"2023120108101142000_64.12.1941.14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0310"},{"key":"2023120108101142000_64.12.1941.15","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.fob.2013.12.001","article-title":"Quantitation of fibroblast activation protein (FAP)\u2013specific protease activity in mouse, baboon and human fluids and organs","volume":"4","author":"Keane","year":"2013","journal-title":"FEBS Open Bio."},{"key":"2023120108101142000_64.12.1941.16","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.210443"},{"key":"2023120108101142000_64.12.1941.17","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.224469"},{"key":"2023120108101142000_64.12.1941.18","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1007\/s00259-022-05842-5","article-title":"Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy","volume":"49","author":"Zboralski","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023120108101142000_64.12.1941.19","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1080\/14728222.2017.1370455","article-title":"Fibroblast activation protein-\u03b1 in fibrogenic disorders and cancer: more than a prolyl-specific peptidase?","volume":"21","author":"Juillerat-Jeanneret","year":"2017","journal-title":"Expert Opin Ther Targets."},{"key":"2023120108101142000_64.12.1941.20","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.112.111021"},{"key":"2023120108101142000_64.12.1941.21","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1007\/s11307-018-01302-5","article-title":"Clinical translation of [68Ga]Ga-NOTA-anti-MMR-sdAb for PET\/CT imaging of protumorigenic macrophages","volume":"21","author":"Xavier","year":"2019","journal-title":"Mol Imaging Biol."},{"key":"2023120108101142000_64.12.1941.22","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.3390\/ijms22031046","article-title":"Regulation of fibroblast activation protein by transforming growth factor beta-1 in glioblastoma microenvironment","volume":"22","author":"Krepela","year":"2021","journal-title":"Int J Mol Sci."},{"key":"2023120108101142000_64.12.1941.23","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-019-04444-y"},{"key":"2023120108101142000_64.12.1941.24","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.208348"},{"key":"2023120108101142000_64.12.1941.25","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.cbpa.2021.06.008","article-title":"Reducing the renal retention of low- to moderate-molecular-weight radiopharmaceuticals","volume":"63","author":"Chigoho","year":"2021","journal-title":"Curr Opin Chem Biol."},{"key":"2023120108101142000_64.12.1941.26","first-page":"S1232","article-title":"Ac-225-DOTATOC: an empiric dose finding for alpha particle emitter based radionuclide therapy of neuroendocrine tumors [abstract]","volume":"56","author":"Kratochwil","year":"2015","journal-title":"J Nucl Med."},{"key":"2023120108101142000_64.12.1941.27","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.191395"},{"key":"2023120108101142000_64.12.1941.28","doi-asserted-by":"crossref","first-page":"265","DOI":"10.23736\/S1824-4785.20.03266-5","article-title":"Targeted alpha therapy: a critical review of translational dosimetry research with emphasis on actinium-225","volume":"64","author":"Castillo Seoane","year":"2020","journal-title":"Q J Nucl Med Mol Imaging."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.123.266381","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T16:13:13Z","timestamp":1701447193000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.123.266381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":28,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12,1]]},"published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.2967\/jnumed.123.266381"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.123.266381","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12]]}}}